Bloodborne biomolecular markers in prostate cancer development and progression

Nature Reviews Cancer

Volumn 2, Issue 12, 2002, Pages 918-926

  Bok, Robert A ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOCETAXEL; ESTRAMUSTINE; FLUTAMIDE; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; GROWTH PROMOTOR; HORMONE; SERINE PROTEINASE;

ALOPECIA; ANEMIA; BLOOD; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER THERAPY; CORRELATION ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; FATIGUE; FLUSHING; HUMAN; LIBIDO DISORDER; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; TUMOR GROWTH; VALIDATION PROCESS; CELL DIVISION; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR;

CELL DIVISION; DISEASE PROGRESSION; GROWTH SUBSTANCES; HORMONES; HUMANS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 0036884307     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc951     Document Type: Review

References (88)

1. Hayes, D. F. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Recent Results Cancer Res. 152, 71-85 (1998).
2. Whitesel, J. A. et al. Acid phosphatase: its influence on the management of carcinoma of the prostate. J. Urol. 131, 70-72 (1984).
3. Gutman, E. B., Sproul, E. E. & Gutman, A. B. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 28, 485-495 (1936).
4. Lowe, F. C. & Trauzzi, S. J. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol. Clin. N. Am. 20, 589-595 (1993).
5. Hara, M., Koyanagi, Y., Inoue, T. & Fukuyama, T. [Some physico-chemical characteristics of 'seminoprotein', an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. Nippon. Hoigaku. Zasshi 25, 322-324 (1971).
6. Wang, M. C., Valenzuela, L. A., Murphy, G. P. & Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol. 17, 159-163 (1979).
7. Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N. Engl. J. Med. 317, 909-916 (1987). Seminal article describing the clinical utility of PSA and its sensitivity for detecting both advanced and early-stage prostate cancer, as well as recurrence after prostatectomy.
8. Stamey, T. A. et al. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Urol. Nephrol. 162 (Suppl.), 73-87 (1994).
9. Lilja, H., Oldbring, J., Rannevik, G. & Laurell, C. B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. 80, 281-285 (1987).
10. Cohen, P. et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75, 1046-1053 (1992).
11. Pollak, M., Beamer, W. & Zhang, J. C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 17, 383-390 (1998).
12. Sutkowski, D. M. et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J. Natl Cancer Inst. 91, 1663-1669 (1999).
13. Killian, C. S., Corral, D. A., Kawinski, E. & Constantine, R. I. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192, 940-947 (1993).
14. Webber, M. M., Waghray, A. & Bello, D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089-1094 (1995).
15. Small, E. J. et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J. Clin. Oncol. 19, 1304-1311 (2001).
16. Stege, R., Grande, M., Carlstrom, K., Tribukait, B. & Pousette, A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 6, 160-165 (2000).
17. Balbay, M. D. et al. Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in vivo and in vitro. Proc. Am. Assoc. Cancer Res. 40, 225-226 (1999).
18. Fortier, A. H., Nelson, B. J., Grella, D. K. & Holaday, J. W. Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91, 1635-1640 (1999).
19. Pretlow, T. G. et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int. J. Cancer 49, 645-649 (1991).
20. Papsidero, L. D., Wang, M. C., Valenzuela, L. A., Murphy, G. P. & Chu, T. M. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428-2432 (1980). Describes the identification of PSA in serum and prostate tissue and its selective increase in prostate cancer patients' sera versus patients with other carcinomas.
21. Oesterling, J. E. et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 50, 13-18 (1997).
22. Bangma, C. H. & Verhagen, P. C. Blood and serum substances for markers of prostate cancer. Microsc. Res. Tech. 51, 430-435 (2000).
23. Culkin, D. J. & Agha, A. H. Localized prostate cancer: an update. Hosp. Med. 33. 25-46 (1997).
24. Miyake, H., Hara, I., Yamanaka, K., Arakawa, S. & Kamidono, S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int. J. Oncol. 14, 535-541 (1999).
25. Miyake, H. et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39, 123-129 (1999).
26. Hienert, G., Kirchheimer, J. C., Pfluger, H. & Binder, B. R. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J. Urol. 140, 1466-1469 (1988).
27. Takeuchi, T., Shuman, M. A. & Craik, C. S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl Acad. Sci. USA 96, 11054-11061 (1999).
28. Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D. & Partin, A. W. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275-368 (1998).
29. Yu. J. X., Chao, L. & Chao, J. Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J. Biol. Chem. 269, 18843-18848 (1994).
30. Dhanesekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
31. Hooper, J. D., Clements, J. A., Quigley, J. P. & Antalis, T. M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860 (2001).
32. Petrow, V. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 9, 343-361 (1986).
33. Denmeade, S. R. & Isaacs, J. T. A history of prostate cancer treatment. Nature Rev. Cancer 2, 389-396 (2002).
34. Hovenian, M. S. & Deming, C. L. The heterologous growth of cancer of the human prostate. Gynecol. Obstet. 86, 29-35 (1948).
35. Wynder, E. L., Laakso, K, Sotarauta, M. & Rose, D. P. Metabolic epidemiology of prostatic cancer. Prostate 5, 47-53 (1984).
36. Farnsworth, W. E. & Brown, J. R. Androgen of the human prostate. Endocr. Res. Commun. 3, 105-117 (1976).
37. Rose, D. P., Laakso, K., Sotarauta, M. & Wynder, E. L. Hormone levels in prostatic fluid from healthy finns and prostate cancer patients. Eur. J. Cancer Clin. Oncol. 20, 1317-1319 (1984).
38. Barrett-Connor, E., Garland, C., McPhillips, J. B., Khaw, K. T. & Wingard, D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 50, 169-173 (1990). The first prospective study of the association between sex hormone levels and incidence of prostate cancer in 1,000 men over a 14-year period.
39. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W. & Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409 (1993).
40. George, D. J. et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 7, 1932-1936 (2001).
41. Bok, R. A. et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61, 2533-2536 (2001).
42. Underholm, B., Tavelin, B., Grankvist, K. & Henriksson, R. CD31, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) discriminate between subgroups of 827 patients: different angiogenic pathways in human breast cancer? Proc. Am. Soc. Clin. Oncol. 19, 646a (2000).
43. Yoshikawa, T. et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett. 153, 7-12 (2000).
44. Kondo, S., Asano, M., Matsuo, K., Ohmori, I. & Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta 1221, 211-214 (1994).
45. Rodriguez, C. R., Fei, D. T., Keyt, B. & Baly, D. L. A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor 165 in human plasma. J. Immunol. Methods 219, 45-55 (1998).
46. Poon, R. T., Fan, S. T. & Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19, 1207-1225 (2001).
47. Battistini, B. D'Orleans-Juste, P. & Sirols, P. Endothelins circulating plasma levels and presence in other biologic fluids. Lab. Invest. 68, 600-628 (1993).
48. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1,944-949 (1995). Report describing the significant increase of endothelin-1 in blood of advanced prostate cancer patients and data implicating endothelin-1 in the osteoblastic reaction in bone metastases.
49. Kopetz, E. S., Nelson, J. B. & Carducci, M. A. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs 20, 173-182 (2002).
50. McWilliam, L. J., Manson, C. & George, N. J. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br. J. Urol. 80, 287-290 (1997).
51. Weinstein, M. H., Partin, A. W., Veltri, R. W. & Epstein, J. I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum. Pathol. 27, 683-687 (1996).
52. Cussenot, O., Villette, J. M., Cochand-Priollet, B. & Berthon, P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate 8 (Suppl.), 43-51 (1998).
53. Abrahamsson, P. A. Neuroendocrine differentiation in prostatic carcinoma. Prostate 39, 135-148 (1999).
54. Ather, M. H. & Abbas, F. Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur. Urol. 38, 535-542 (2000).
55. Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002). One of the first studies using microarray expression analysis of human prostate cancers that attempted to correlate expression-profile changes with clinical outcomes.
56. Rajah, R., Valentinis, B. & Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272, 12181-12188 (1997).
57. Chan, J. M. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566 (1998). Prospective study of blood levels of IGF1 in healthy men, showing that men with the highest levels had a fourfold increased risk of developing prostate cancer.
58. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. & Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst. 88, 1118-1126 (1996).
59. Berruti, A. et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 47, 205-211 (2001).
60. Huggins, C. & Hodges, C. V. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941). Classic article describing the response of prostate cancer to hormonal therapy, which heralded a new era of treatment options, especially for advanced prostate cancer patients.
61. Bellows, C. G., Aubin, J. E. & Heersche, J. N. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner. 14, 27-40 (1991).
62. Fontana, A. & Delmas, P. D. Markers of bone turnover in bone metastases. Cancer 88, 2952-2960 (2000).
63. Garnero, P. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858-864 (2000).
64. Hill, C. S. & Wolfert, R. L. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin. Chim. Acta 186, 315-320 (1990).
65. Wymenga, L. F. et al. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int. 88, 231-235 (2001).
66. Strum, S. B. The concerns of an oncologist. PCR Insights 4, 8-10 (2001).
67. Stoch, S. A. et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J. Clin. Endocrinol Metab. 86, 2787-2791 (2001).
68. Meijer, W. G., van der Veer, E. & Willemse, P. H. Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncol. Rep. 5, 5-21 (1998).
69. Berenson, J. R. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin. Oncol. 28, 25-34 (2001).
70. FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev. Anticancer Ther. 2, 137-138 (2002).
71. Sumitomo, M. et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res. 61, 3294-3298 (2001).
72. Sasaki, T., Hohenester, E. & Timpl, R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 53, 77-84 (2002).
73. Beckett, M. L., Cazares, L. H., Vlahou, A., Schellhammer, P. F. & Wright, G. L. Jr. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin. Cancer Res. 5, 4034-4040 (1999). An analysis of 263 patients, showing increase of serum levels of PSMA in prostate cancer patients, and also in BPH, prostatitis, and in patients with other malignancies. Statistical differences in levels was evident only between benign conditions and advanced (T3) prostate cancers.
74. Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198 (1999).
75. Reiter, R. E. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735-1740 (1998).
76. Moreno, J. G. et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 52, 6110-6112 (1992).
77. Yao, K. L., Pilat, M. J. & Pienta, K. J. Reverse transcriptase polymerase chain reaction (RT-PCR) to detect prostate cancer micrometastasis in the blood. Cancer Treat. Res. 88, 77-91 (1996).
78. Kantoff, P. W. et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J. Clin. Oncol. 19, 3025-3028 (2001).
79. Weckermann, D. et al. Micrometastases of bona marrow in localized prostate cancer: correlation with established risk factors. J. Clin. Oncol. 17, 3438-3443 (1999).
80. Ghossein, R. A. & Bhattacharya, S. Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin. Surg. Oncol. 20, 304-311 (2001).
81. Adam, B. L. et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614 (2002). Use of SELDI-TOF mass spectrometry to perform proteomic analysison on sera from prostate cancer patients and people with benign conditions or no disease. A high specificity of 97% and a positive predictive value of 96% was seen in detecting early prostate cancer.
82. Srinivas, P. R., Srivastava, S., Hanash, S. Wright, G.L. Jr. Proteomics in early detection of cancer. Clin. Chem. 47, 1901-1911 (2001).
83. Petricoin, E. F. et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst 94, 1576-1578 (2002).
84. Meehan, K. L., Holland, J. W. & Dawkins, H. J. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50, 54-63 (2002).
85. Altwein, J. E. & Luboldt, H. J. Prognostic factors for carcinoma of the prostate. Urol. Int. 63, 62-71 (1999).
86. Dmochowski, A. & Assenhajm, D. uber Harn-und Blut-phosphate. Naturwissen-schaften 23, 501 (1935).
87. Kutscher, W. & Worner, A. Prostatophosphate. Physiol. Chem. 239, 109 (1936).
88. Watanabe, H. et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 75, 229-235 (1991).